Genomic landscape of non-small-cell lung cancer with methylthioadenosine phosphorylase (MTAP) deficiency.

Prashanth Ashok KumarStephen L GrazianoNatalie DanzigerDean PavlickEric A SeversonShakti H RamkissoonRichard S P HuangBrennan DeckerJeffrey S Ross

Published in: Cancer medicine (2022)

MTAP loss occurs in 13% of NSCLC, supporting the development of targeted therapies to exploit PRMT5 hyper-dependence. MTAP loss is accompanied by small differences in targeted and immunotherapy options which may impact future combination strategies.

Keyphrases

small cell lung cancer
current status
single cell
copy number
advanced non small cell lung cancer
replacement therapy
gene expression
drug delivery
smoking cessation